Somatostatin receptor scintigraphy in the follow-up of myasthenia gravis.
To evaluate the potential value of somatostatin receptor scintigraphy (SRS) using 111In-DTPA (diethylenetriaminepenta acetic acid)-D-Phe1-octreotide (111In-pentetreotide) in patients with recurring or persisting symptoms of myasthenia gravis (MG), 14 consecutive cases with such supplemental receptor imaging during neurological routine follow-up were retrospectively evaluated in this study. All 14 patients underwent SRS in addition to chest computed tomography (CT). Mean follow-up after imaging was 34 months. Eight patients had previous thymectomy, and three patients were referred to surgery after scintigraphy and chest CT. SRS was positive in one of the 14 patients with local recurrence of thymoma and pleural invasion, and negative in the remaining 13 patients. CT was positive for thymoma in three patients, inconclusive in four patients and negative in seven patients. In conclusion, while SRS may be able to detect thymoma lesions including metastases, it seems of limited value in patients with inconspicuous CT findings. Our initial experience fails to point out a benefit of SRS in the management of persisting or recurring MG (with regard to detection of thymic disorders) compared to CT. Whether SRS is useful for differentiating thymoma from non-neoplastic thymic disease may be investigated by larger series. A predominant proportion of patients with unsatisfactory treatment response, however, continue to suffer an unfavourable clinical course despite absent evidence for thymic pathology.
Gao
Z R
ZR
Department of Nuclear Medicine Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kornblum
C
C
Flacke
S
S
Logvinski
T
T
Yüksel
M
M
An
R
R
Klockgether
T
T
Biersack
H J
HJ
Ezziddin
S
S
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000000981:diagnostic imaging*; D015282:Octreotide / Q000031:analogs & derivatives; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin / Q000032:analysis*; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
D007457:Iodine Radioisotopes; D017481:Receptors, Somatostatin; D015282:Octreotide
Intern Med. 2004 Mar;43(3):189-93
15098598
Blood. 1993 Oct 1;82(7):2143-51
8400264
Asian Cardiovasc Thorac Ann. 2003 Dec;11(4):299-303
14681088
Eur J Nucl Med. 1993 Aug;20(8):716-31
8404961
Cancer. 2002 Mar 1;94(5):1414-20
11920496
Acta Neurol Scand. 2004 Mar;109(3):217-21
14763961
Radiology. 2001 Oct;221(1):201-6
11568341
J Thorac Cardiovasc Surg. 2003 Dec;126(6):1922-8
14688707
J Clin Oncol. 2004 Jan 15;22(2):293-9
14722038
J Nucl Med. 1998 Apr;39(4):634-9
9544670
Ann Med. 1999 Oct;31 Suppl 2:63-9
10574158
Pathol Res Pract. 1999;195(8):575-81
10483589
Endocr Rev. 1991 Nov;12(4):450-82
1684746
Ann Med. 1999 Oct;31 Suppl 2:57-62
10574157
Clin Nucl Med. 1999 Jan;24(1):24-8
9890489
Asian Cardiovasc Thorac Ann. 2003 Dec;11(4):323-7
14681093
Ann N Y Acad Sci. 2003 Sep;998:473-80
14592916
Radiology. 1996 Nov;201(2):471-4
8888243
Acta Radiol. 2002 Jul;43(4):380-4
12225479
Chin Med J (Engl). 2003 Oct;116(10):1578-81
14640105
J Clin Neurosci. 2004 Aug;11(6):610-3
15261231
Tidsskr Nor Laegeforen. 2004 Mar 4;124(5):629-31
15004605